aluates Reports

$ 0.0

Automative

Global Nucleic Acid Drugs Market Research Report 2026

Published Date: 2026-04-24

Report Code: QYRE-Auto-6M12952

Global Nucleic Acid Drugs Market Size Status and Forecast 2022 2028

BUY CHAPTERS

Global Nucleic Acid Drugs Market Research Report 2026

Code: QYRE-Auto-6M12952

Report

2026-04-24

Pages:115

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

Sarepta Therapeutics

Ionis Pharmaceuticals

Alnylam

BioNTech

Nippon Shinyaku

Moderna Therapeutics

Biogen

SOBI

Novartis

Pfizer Inc

Jazz Pharmaceuticals

Novo Nordisk

Astrazeneca plc

Astellas Pharma

Nucleic Acid Drugs Market Size

The global Nucleic Acid Drugs market was valued at US$ 14060 million in 2025 and is anticipated to reach US$ 23200 million by 2032, at a CAGR of 7.5% from 2026 to 2032.

Nucleic Acid Drugs Market

Nucleic acid drugs, also known as nucleic acid-based therapeutics, are a class of pharmaceuticals designed to treat various diseases by targeting specific genes or genetic processes within the human body. They are distinct from traditional small molecule drugs and instead rely on nucleic acids, which are the building blocks of genetic information. Nucleic acid drugs encompass various types of pharmaceuticals that use nucleic acids, such as DNA or RNA, as their active components to target specific genes or genetic processes. Nucleic acid drugs are being developed as novel therapeutic modalities. They have great potential to treat human diseases such as cancers, viral infections, and genetic disorders due to unique characteristics that make it possible to approach undruggable targets using classical small molecule or protein/antibody-based biologics. Currently, mRNA vaccines, small interfering RNA (siRNA, small interfering RNA) and antisense nucleic acids (ASO, antisense oligodeoxyncleotides) are the main forms of nucleic acid drug development in clinical practice.

The nucleic acid drugs market is primarily driven by the increasing understanding of genetic and molecular mechanisms underlying diseases, leading to the development of targeted therapies. Breakthroughs in genomics, such as the Human Genome Project, have enabled the identification of specific genes and genetic mutations associated with various diseases, spurring the development of nucleic acid-based treatments. Additionally, the growing demand for personalized medicine, where therapies are tailored to an individual's genetic profile, is propelling the adoption of nucleic acid drugs. Moreover, advancements in drug delivery technologies, including nanoparticles and viral vectors, are enhancing the effectiveness and safety of these therapies, further driving market growth.

Despite the promising potential of nucleic acid drugs, several challenges exist in the market. One significant challenge is the efficient delivery of nucleic acids to target cells and tissues, as they are often susceptible to degradation and immune responses. Off-target effects, such as unintended genetic alterations, and safety concerns are also important challenges that require rigorous clinical testing and validation. Additionally, the high development costs and lengthy regulatory processes for nucleic acid drugs pose financial and time-related challenges for pharmaceutical companies. Ensuring long-term stability, scalability, and cost-effectiveness of manufacturing these complex biologics is another key challenge in the market.

The future development of nucleic acid drugs is expected to be defined by technological innovation, delivery optimization, and expanding therapeutic applications beyond rare genetic diseases. Over the next decade, the field will likely transition from niche indications toward broader clinical use, driven by the maturation of RNA interference (RNAi), antisense oligonucleotides (ASOs), mRNA therapies, aptamers, and gene-editing platforms. A major focus will be on improving delivery systems—particularly ligand-conjugated and lipid nanoparticle (LNP) technologies—that enable precise targeting of extrahepatic tissues such as the central nervous system, muscle, and tumor microenvironments. Advances in chemical modification and backbone engineering are expected to enhance molecular stability, reduce immunogenicity, and prolong duration of action, making nucleic acid drugs more suitable for chronic conditions. Moreover, the integration of AI-driven sequence design and bioinformatics will accelerate candidate optimization and personalized drug development, leading to faster, more cost-effective R&D pipelines. In parallel, the commercial and regulatory landscape for nucleic acid drugs is becoming more favorable. Increasing numbers of successful approvals—such as siRNA and ASO therapies targeting metabolic, neurological, and cardiovascular disorders—have validated this modality and encouraged greater investment from both large pharmaceutical companies and biotech startups. The average gross profit margin of this product is 85%.

This report delivers a comprehensive overview of the global Nucleic Acid Drugs market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Nucleic Acid Drugs. The Nucleic Acid Drugs market size, estimates, and forecasts are provided in terms of revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.

The report segments the global Nucleic Acid Drugs market comprehensively. Regional market sizes by Type, by Application, by Delivery Technology, and by player are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.

This report will assist Nucleic Acid Drugs manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Market Segmentation

Scope of Nucleic Acid Drugs Market Report

Report Metric	Details
Report Name	Nucleic Acid Drugs Market
Accounted market size in 2025	US$ 14060 in million
Forecasted market size in 2032	US$ 23200 million
CAGR	7.5%
Base Year	2025
Forecasted years	2026 - 2032
Segment by Type	Antisense Oligonucleotides (ASO) siRNA mRNA Other
Segment by Delivery Technology	Lipid Nanoparticles Polymeric Nanocarriers Viral Vectors Other
Segment by Sales Channels	Hospital Clinic Other
Segment by Application	Neuromuscular Diseases hATTR COVID-19 Other
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Sarepta Therapeutics, Ionis Pharmaceuticals, Alnylam, Biogen, Nippon Shinyaku, Sobi, Novartis, BioNTech, Pfizer, Moderna Therapeutics, Jazz Pharmaceuticals, Novo Nordisk, AstraZeneca, Astellas Pharma
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, by Delivery Technology, etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Summarizes global and regional market size and outlines market dynamics and recent developments, including key drivers, restraints, challenges and risks for industry participants, and relevant policy analysis.
Chapter 3: Provides a detailed view of the competitive landscape for Nucleic Acid Drugs companies, covering revenue share, development plans, and mergers and acquisitions.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify blue-ocean opportunities.
Chapter 5: Analyzes segments by Application, detailing the size and growth potential of each downstream segment to help readers identify blue-ocean opportunities.
Chapter 6–10: Regional deep dives (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) broken down by country. Each chapter quantifies market size and growth potential by region and key countries, and outlines market development, outlook, addressable space, and capacity.
Chapter 11: Profiles key players, presenting essential information on leading companies, including product/ service offerings, revenue, gross margin, product introductions/portfolios, recent developments, etc.
Chapter 12: Key findings and conclusions of the report.

FAQ for this report

How fast is Nucleic Acid Drugs Market growing?

Ans: The Nucleic Acid Drugs Market witnessing a CAGR of 7.5% during the forecast period 2026-2032.

What is the Nucleic Acid Drugs Market size in 2032?

Ans: The Nucleic Acid Drugs Market size in 2032 will be US$ 23200 million.

Who are the main players in the Nucleic Acid Drugs Market report?

Ans: The main players in the Nucleic Acid Drugs Market are Sarepta Therapeutics, Ionis Pharmaceuticals, Alnylam, Biogen, Nippon Shinyaku, Sobi, Novartis, BioNTech, Pfizer, Moderna Therapeutics, Jazz Pharmaceuticals, Novo Nordisk, AstraZeneca, Astellas Pharma

What are the Application segmentation covered in the Nucleic Acid Drugs Market report?

Ans: The Applications covered in the Nucleic Acid Drugs Market report are Neuromuscular Diseases, hATTR, COVID-19, Other

What are the Type segmentation covered in the Nucleic Acid Drugs Market report?

Ans: The Types covered in the Nucleic Acid Drugs Market report are Antisense Oligonucleotides (ASO), siRNA, mRNA, Other

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Nucleic Acid Drugs Market Size Growth Rate by Type: 2021 vs 2025 vs 2032

1.2.2 Antisense Oligonucleotides (ASO)

1.2.3 siRNA

1.2.4 mRNA

1.2.5 Other

1.3 Market by Delivery Technology

1.3.1 Global Nucleic Acid Drugs Market Size Growth Rate by Delivery Technology: 2021 vs 2025 vs 2032

1.3.2 Lipid Nanoparticles

1.3.3 Polymeric Nanocarriers

1.3.4 Viral Vectors

1.3.5 Other

1.4 Market by Sales Channels

1.4.1 Global Nucleic Acid Drugs Market Size Growth Rate by Sales Channels: 2021 vs 2025 vs 2032

1.4.2 Hospital

1.4.3 Clinic

1.4.4 Other

1.5 Market by Application

1.5.1 Global Nucleic Acid Drugs Market Growth by Application: 2021 vs 2025 vs 2032

1.5.2 Neuromuscular Diseases

1.5.3 hATTR

1.5.4 COVID-19

1.5.5 Other

1.6 Assumptions and Limitations

1.7 Study Objectives

1.8 Years Considered

2 Global Growth Trends

2.1 Global Nucleic Acid Drugs Market Perspective (2021–2032)

2.2 Global Nucleic Acid Drugs Growth Trends by Region

2.2.1 Global Nucleic Acid Drugs Market Size by Region: 2021 vs 2025 vs 2032

2.2.2 Nucleic Acid Drugs Historic Market Size by Region (2021–2026)

2.2.3 Nucleic Acid Drugs Forecasted Market Size by Region (2027–2032)

2.3 Nucleic Acid Drugs Market Dynamics

2.3.1 Nucleic Acid Drugs Industry Trends

2.3.2 Nucleic Acid Drugs Market Drivers

2.3.3 Nucleic Acid Drugs Market Challenges

2.3.4 Nucleic Acid Drugs Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Nucleic Acid Drugs Players by Revenue

3.1.1 Global Top Nucleic Acid Drugs Players by Revenue (2021–2026)

3.1.2 Global Nucleic Acid Drugs Revenue Market Share by Players (2021–2026)

3.2 Global Top Nucleic Acid Drugs Players Market Share by Company Tier (Tier 1, Tier 2, Tier 3)

3.3 Global Key Players Ranking by Nucleic Acid Drugs Revenue

3.4 Global Nucleic Acid Drugs Market Concentration Ratio

3.4.1 Global Nucleic Acid Drugs Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Nucleic Acid Drugs Revenue in 2025

3.5 Global Key Players of Nucleic Acid Drugs Head Offices and Areas Served

3.6 Global Key Players of Nucleic Acid Drugs, Products and Applications

3.7 Global Key Players of Nucleic Acid Drugs, Date of General Availability (GA)

3.8 Mergers and Acquisitions, Expansion Plans

4 Nucleic Acid Drugs Breakdown Data by Type

4.1 Global Nucleic Acid Drugs Historic Market Size by Type (2021–2026)

4.2 Global Nucleic Acid Drugs Forecasted Market Size by Type (2027–2032)

5 Nucleic Acid Drugs Breakdown Data by Application

5.1 Global Nucleic Acid Drugs Historic Market Size by Application (2021–2026)

5.2 Global Nucleic Acid Drugs Forecasted Market Size by Application (2027–2032)

6 North America

6.1 North America Nucleic Acid Drugs Market Size (2021–2032)

6.2 North America Nucleic Acid Drugs Market Growth Rate by Country: 2021 vs 2025 vs 2032

6.3 North America Nucleic Acid Drugs Market Size by Country (2021–2026)

6.4 North America Nucleic Acid Drugs Market Size by Country (2027–2032)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Nucleic Acid Drugs Market Size (2021–2032)

7.2 Europe Nucleic Acid Drugs Market Growth Rate by Country: 2021 vs 2025 vs 2032

7.3 Europe Nucleic Acid Drugs Market Size by Country (2021–2026)

7.4 Europe Nucleic Acid Drugs Market Size by Country (2027–2032)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Ireland

8 Asia-Pacific

8.1 Asia-Pacific Nucleic Acid Drugs Market Size (2021–2032)

8.2 Asia-Pacific Nucleic Acid Drugs Market Growth Rate by Region: 2021 vs 2025 vs 2032

8.3 Asia-Pacific Nucleic Acid Drugs Market Size by Region (2021–2026)

8.4 Asia-Pacific Nucleic Acid Drugs Market Size by Region (2027–2032)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia & New Zealand

9 Latin America

9.1 Latin America Nucleic Acid Drugs Market Size (2021–2032)

9.2 Latin America Nucleic Acid Drugs Market Growth Rate by Country: 2021 vs 2025 vs 2032

9.3 Latin America Nucleic Acid Drugs Market Size by Country (2021–2026)

9.4 Latin America Nucleic Acid Drugs Market Size by Country (2027–2032)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Nucleic Acid Drugs Market Size (2021–2032)

10.2 Middle East & Africa Nucleic Acid Drugs Market Growth Rate by Country: 2021 vs 2025 vs 2032

10.3 Middle East & Africa Nucleic Acid Drugs Market Size by Country (2021–2026)

10.4 Middle East & Africa Nucleic Acid Drugs Market Size by Country (2027–2032)

10.5 Israel

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Sarepta Therapeutics

11.1.1 Sarepta Therapeutics Company Details

11.1.2 Sarepta Therapeutics Business Overview

11.1.3 Sarepta Therapeutics Nucleic Acid Drugs Introduction

11.1.4 Sarepta Therapeutics Revenue in Nucleic Acid Drugs Business (2021–2026)

11.1.5 Sarepta Therapeutics Recent Development

11.2 Ionis Pharmaceuticals

11.2.1 Ionis Pharmaceuticals Company Details

11.2.2 Ionis Pharmaceuticals Business Overview

11.2.3 Ionis Pharmaceuticals Nucleic Acid Drugs Introduction

11.2.4 Ionis Pharmaceuticals Revenue in Nucleic Acid Drugs Business (2021–2026)

11.2.5 Ionis Pharmaceuticals Recent Development

11.3 Alnylam

11.3.1 Alnylam Company Details

11.3.2 Alnylam Business Overview

11.3.3 Alnylam Nucleic Acid Drugs Introduction

11.3.4 Alnylam Revenue in Nucleic Acid Drugs Business (2021–2026)

11.3.5 Alnylam Recent Development

11.4 Biogen

11.4.1 Biogen Company Details

11.4.2 Biogen Business Overview

11.4.3 Biogen Nucleic Acid Drugs Introduction

11.4.4 Biogen Revenue in Nucleic Acid Drugs Business (2021–2026)

11.4.5 Biogen Recent Development

11.5 Nippon Shinyaku

11.5.1 Nippon Shinyaku Company Details

11.5.2 Nippon Shinyaku Business Overview

11.5.3 Nippon Shinyaku Nucleic Acid Drugs Introduction

11.5.4 Nippon Shinyaku Revenue in Nucleic Acid Drugs Business (2021–2026)

11.5.5 Nippon Shinyaku Recent Development

11.6 Sobi

11.6.1 Sobi Company Details

11.6.2 Sobi Business Overview

11.6.3 Sobi Nucleic Acid Drugs Introduction

11.6.4 Sobi Revenue in Nucleic Acid Drugs Business (2021–2026)

11.6.5 Sobi Recent Development

11.7 Novartis

11.7.1 Novartis Company Details

11.7.2 Novartis Business Overview

11.7.3 Novartis Nucleic Acid Drugs Introduction

11.7.4 Novartis Revenue in Nucleic Acid Drugs Business (2021–2026)

11.7.5 Novartis Recent Development

11.8 BioNTech

11.8.1 BioNTech Company Details

11.8.2 BioNTech Business Overview

11.8.3 BioNTech Nucleic Acid Drugs Introduction

11.8.4 BioNTech Revenue in Nucleic Acid Drugs Business (2021–2026)

11.8.5 BioNTech Recent Development

11.9 Pfizer

11.9.1 Pfizer Company Details

11.9.2 Pfizer Business Overview

11.9.3 Pfizer Nucleic Acid Drugs Introduction

11.9.4 Pfizer Revenue in Nucleic Acid Drugs Business (2021–2026)

11.9.5 Pfizer Recent Development

11.10 Moderna Therapeutics

11.10.1 Moderna Therapeutics Company Details

11.10.2 Moderna Therapeutics Business Overview

11.10.3 Moderna Therapeutics Nucleic Acid Drugs Introduction

11.10.4 Moderna Therapeutics Revenue in Nucleic Acid Drugs Business (2021–2026)

11.10.5 Moderna Therapeutics Recent Development

11.11 Jazz Pharmaceuticals

11.11.1 Jazz Pharmaceuticals Company Details

11.11.2 Jazz Pharmaceuticals Business Overview

11.11.3 Jazz Pharmaceuticals Nucleic Acid Drugs Introduction

11.11.4 Jazz Pharmaceuticals Revenue in Nucleic Acid Drugs Business (2021–2026)

11.11.5 Jazz Pharmaceuticals Recent Development

11.12 Novo Nordisk

11.12.1 Novo Nordisk Company Details

11.12.2 Novo Nordisk Business Overview

11.12.3 Novo Nordisk Nucleic Acid Drugs Introduction

11.12.4 Novo Nordisk Revenue in Nucleic Acid Drugs Business (2021–2026)

11.12.5 Novo Nordisk Recent Development

11.13 AstraZeneca

11.13.1 AstraZeneca Company Details

11.13.2 AstraZeneca Business Overview

11.13.3 AstraZeneca Nucleic Acid Drugs Introduction

11.13.4 AstraZeneca Revenue in Nucleic Acid Drugs Business (2021–2026)

11.13.5 AstraZeneca Recent Development

11.14 Astellas Pharma

11.14.1 Astellas Pharma Company Details

11.14.2 Astellas Pharma Business Overview

11.14.3 Astellas Pharma Nucleic Acid Drugs Introduction

11.14.4 Astellas Pharma Revenue in Nucleic Acid Drugs Business (2021–2026)

11.14.5 Astellas Pharma Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

Sarepta Therapeutics

Ionis Pharmaceuticals

Alnylam

BioNTech

Nippon Shinyaku

Moderna Therapeutics

Biogen

SOBI

Novartis

Pfizer Inc

Jazz Pharmaceuticals

Novo Nordisk

Astrazeneca plc

Astellas Pharma

List of Tables

Table 1. Global Nucleic Acid Drugs Market Size Growth Rate by Type (US$ Million): 2021 vs 2025 vs 2032

Table 2. Key Players of Antisense Oligonucleotides (ASO)

Table 3. Key Players of siRNA

Table 4. Key Players of mRNA

Table 5. Key Players of Other

Table 6. Global Nucleic Acid Drugs Market Size Growth Rate by Delivery Technology (US$ Million): 2021 vs 2025 vs 2032

Table 7. Key Players of Lipid Nanoparticles

Table 8. Key Players of Polymeric Nanocarriers

Table 9. Key Players of Viral Vectors

Table 10. Key Players of Other

Table 11. Global Nucleic Acid Drugs Market Size Growth Rate by Sales Channels (US$ Million): 2021 vs 2025 vs 2032

Table 12. Key Players of Hospital

Table 13. Key Players of Clinic

Table 14. Key Players of Other

Table 15. Global Nucleic Acid Drugs Market Size Growth by Application (US$ Million): 2021 vs 2025 vs 2032

Table 16. Global Nucleic Acid Drugs Market Size by Region (US$ Million): 2021 vs 2025 vs 2032

Table 17. Global Nucleic Acid Drugs Market Size by Region (US$ Million), 2021–2026

Table 18. Global Nucleic Acid Drugs Market Share by Region (2021–2026)

Table 19. Global Nucleic Acid Drugs Forecasted Market Size by Region (US$ Million), 2027–2032

Table 20. Global Nucleic Acid Drugs Market Share by Region (2027–2032)

Table 21. Nucleic Acid Drugs Market Trends

Table 22. Nucleic Acid Drugs Market Drivers

Table 23. Nucleic Acid Drugs Market Challenges

Table 24. Nucleic Acid Drugs Market Restraints

Table 25. Global Nucleic Acid Drugs Revenue by Players (US$ Million), 2021–2026

Table 26. Global Nucleic Acid Drugs Market Share by Players (2021–2026)

Table 27. Global Top Nucleic Acid Drugs Players by Tier (Tier 1, Tier 2, and Tier 3), based on Nucleic Acid Drugs Revenue, 2025

Table 28. Ranking of Global Top Nucleic Acid Drugs Companies by Revenue (US$ Million) in 2025

Table 29. Global 5 Largest Players Market Share by Nucleic Acid Drugs Revenue (CR5 and HHI), 2021–2026

Table 30. Global Key Players of Nucleic Acid Drugs, Headquarters and Area Served

Table 31. Global Key Players of Nucleic Acid Drugs, Products and Applications

Table 32. Global Key Players of Nucleic Acid Drugs, Date of General Availability (GA)

Table 33. Mergers and Acquisitions, Expansion Plans

Table 34. Global Nucleic Acid Drugs Market Size by Type (US$ Million), 2021–2026

Table 35. Global Nucleic Acid Drugs Revenue Market Share by Type (2021–2026)

Table 36. Global Nucleic Acid Drugs Forecasted Market Size by Type (US$ Million), 2027–2032

Table 37. Global Nucleic Acid Drugs Revenue Market Share by Type (2027–2032)

Table 38. Global Nucleic Acid Drugs Market Size by Application (US$ Million), 2021–2026

Table 39. Global Nucleic Acid Drugs Revenue Market Share by Application (2021–2026)

Table 40. Global Nucleic Acid Drugs Forecasted Market Size by Application (US$ Million), 2027–2032

Table 41. Global Nucleic Acid Drugs Revenue Market Share by Application (2027–2032)

Table 42. North America Nucleic Acid Drugs Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 43. North America Nucleic Acid Drugs Market Size by Country (US$ Million), 2021–2026

Table 44. North America Nucleic Acid Drugs Market Size by Country (US$ Million), 2027–2032

Table 45. Europe Nucleic Acid Drugs Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 46. Europe Nucleic Acid Drugs Market Size by Country (US$ Million), 2021–2026

Table 47. Europe Nucleic Acid Drugs Market Size by Country (US$ Million), 2027–2032

Table 48. Asia-Pacific Nucleic Acid Drugs Market Size Growth Rate by Region (US$ Million): 2021 vs 2025 vs 2032

Table 49. Asia-Pacific Nucleic Acid Drugs Market Size by Region (US$ Million), 2021–2026

Table 50. Asia-Pacific Nucleic Acid Drugs Market Size by Region (US$ Million), 2027–2032

Table 51. Latin America Nucleic Acid Drugs Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 52. Latin America Nucleic Acid Drugs Market Size by Country (US$ Million), 2021–2026

Table 53. Latin America Nucleic Acid Drugs Market Size by Country (US$ Million), 2027–2032

Table 54. Middle East & Africa Nucleic Acid Drugs Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 55. Middle East & Africa Nucleic Acid Drugs Market Size by Country (US$ Million), 2021–2026

Table 56. Middle East & Africa Nucleic Acid Drugs Market Size by Country (US$ Million), 2027–2032

Table 57. Sarepta Therapeutics Company Details

Table 58. Sarepta Therapeutics Business Overview

Table 59. Sarepta Therapeutics Nucleic Acid Drugs Product

Table 60. Sarepta Therapeutics Revenue in Nucleic Acid Drugs Business (US$ Million), 2021–2026

Table 61. Sarepta Therapeutics Recent Development

Table 62. Ionis Pharmaceuticals Company Details

Table 63. Ionis Pharmaceuticals Business Overview

Table 64. Ionis Pharmaceuticals Nucleic Acid Drugs Product

Table 65. Ionis Pharmaceuticals Revenue in Nucleic Acid Drugs Business (US$ Million), 2021–2026

Table 66. Ionis Pharmaceuticals Recent Development

Table 67. Alnylam Company Details

Table 68. Alnylam Business Overview

Table 69. Alnylam Nucleic Acid Drugs Product

Table 70. Alnylam Revenue in Nucleic Acid Drugs Business (US$ Million), 2021–2026

Table 71. Alnylam Recent Development

Table 72. Biogen Company Details

Table 73. Biogen Business Overview

Table 74. Biogen Nucleic Acid Drugs Product

Table 75. Biogen Revenue in Nucleic Acid Drugs Business (US$ Million), 2021–2026

Table 76. Biogen Recent Development

Table 77. Nippon Shinyaku Company Details

Table 78. Nippon Shinyaku Business Overview

Table 79. Nippon Shinyaku Nucleic Acid Drugs Product

Table 80. Nippon Shinyaku Revenue in Nucleic Acid Drugs Business (US$ Million), 2021–2026

Table 81. Nippon Shinyaku Recent Development

Table 82. Sobi Company Details

Table 83. Sobi Business Overview

Table 84. Sobi Nucleic Acid Drugs Product

Table 85. Sobi Revenue in Nucleic Acid Drugs Business (US$ Million), 2021–2026

Table 86. Sobi Recent Development

Table 87. Novartis Company Details

Table 88. Novartis Business Overview

Table 89. Novartis Nucleic Acid Drugs Product

Table 90. Novartis Revenue in Nucleic Acid Drugs Business (US$ Million), 2021–2026

Table 91. Novartis Recent Development

Table 92. BioNTech Company Details

Table 93. BioNTech Business Overview

Table 94. BioNTech Nucleic Acid Drugs Product

Table 95. BioNTech Revenue in Nucleic Acid Drugs Business (US$ Million), 2021–2026

Table 96. BioNTech Recent Development

Table 97. Pfizer Company Details

Table 98. Pfizer Business Overview

Table 99. Pfizer Nucleic Acid Drugs Product

Table 100. Pfizer Revenue in Nucleic Acid Drugs Business (US$ Million), 2021–2026

Table 101. Pfizer Recent Development

Table 102. Moderna Therapeutics Company Details

Table 103. Moderna Therapeutics Business Overview

Table 104. Moderna Therapeutics Nucleic Acid Drugs Product

Table 105. Moderna Therapeutics Revenue in Nucleic Acid Drugs Business (US$ Million), 2021–2026

Table 106. Moderna Therapeutics Recent Development

Table 107. Jazz Pharmaceuticals Company Details

Table 108. Jazz Pharmaceuticals Business Overview

Table 109. Jazz Pharmaceuticals Nucleic Acid Drugs Product

Table 110. Jazz Pharmaceuticals Revenue in Nucleic Acid Drugs Business (US$ Million), 2021–2026

Table 111. Jazz Pharmaceuticals Recent Development

Table 112. Novo Nordisk Company Details

Table 113. Novo Nordisk Business Overview

Table 114. Novo Nordisk Nucleic Acid Drugs Product

Table 115. Novo Nordisk Revenue in Nucleic Acid Drugs Business (US$ Million), 2021–2026

Table 116. Novo Nordisk Recent Development

Table 117. AstraZeneca Company Details

Table 118. AstraZeneca Business Overview

Table 119. AstraZeneca Nucleic Acid Drugs Product

Table 120. AstraZeneca Revenue in Nucleic Acid Drugs Business (US$ Million), 2021–2026

Table 121. AstraZeneca Recent Development

Table 122. Astellas Pharma Company Details

Table 123. Astellas Pharma Business Overview

Table 124. Astellas Pharma Nucleic Acid Drugs Product

Table 125. Astellas Pharma Revenue in Nucleic Acid Drugs Business (US$ Million), 2021–2026

Table 126. Astellas Pharma Recent Development

Table 127. Research Programs/Design for This Report

Table 128. Key Data Information from Secondary Sources

Table 129. Key Data Information from Primary Sources

Table 130. Authors List of This Report

List of Figures

Figure 1. Nucleic Acid Drugs Picture

Figure 2. Global Nucleic Acid Drugs Market Size Comparison by Type (US$ Million), 2021–2032

Figure 3. Global Nucleic Acid Drugs Market Share by Type: 2025 vs 2032

Figure 4. Antisense Oligonucleotides (ASO) Features

Figure 5. siRNA Features

Figure 6. mRNA Features

Figure 7. Other Features

Figure 8. Global Nucleic Acid Drugs Market Size Comparison by Delivery Technology (US$ Million), 2021–2032

Figure 9. Lipid Nanoparticles Features

Figure 10. Polymeric Nanocarriers Features

Figure 11. Viral Vectors Features

Figure 12. Other Features

Figure 13. Global Nucleic Acid Drugs Market Size Comparison by Sales Channels (US$ Million), 2021–2032

Figure 14. Hospital Features

Figure 15. Clinic Features

Figure 16. Other Features

Figure 17. Global Nucleic Acid Drugs Market Size by Application (US$ Million), 2021–2032

Figure 18. Global Nucleic Acid Drugs Market Share by Application: 2025 vs 2032

Figure 19. Neuromuscular Diseases Case Studies

Figure 20. hATTR Case Studies

Figure 21. COVID-19 Case Studies

Figure 22. Other Case Studies

Figure 23. Nucleic Acid Drugs Report Years Considered

Figure 24. Global Nucleic Acid Drugs Market Size (US$ Million), Year-over-Year: 2021–2032

Figure 25. Global Nucleic Acid Drugs Market Size, (US$ Million), 2021 vs 2025 vs 2032

Figure 26. Global Nucleic Acid Drugs Market Share by Region: 2025 vs 2032

Figure 27. Global Nucleic Acid Drugs Market Share by Players in 2025

Figure 28. Global Nucleic Acid Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

Figure 29. The Top 10 and 5 Players Market Share by Nucleic Acid Drugs Revenue in 2025

Figure 30. North America Nucleic Acid Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 31. North America Nucleic Acid Drugs Market Share by Country (2021–2032)

Figure 32. United States Nucleic Acid Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 33. Canada Nucleic Acid Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 34. Europe Nucleic Acid Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 35. Europe Nucleic Acid Drugs Market Share by Country (2021–2032)

Figure 36. Germany Nucleic Acid Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 37. France Nucleic Acid Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 38. U.K. Nucleic Acid Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 39. Italy Nucleic Acid Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 40. Russia Nucleic Acid Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 41. Ireland Nucleic Acid Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 42. Asia-Pacific Nucleic Acid Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 43. Asia-Pacific Nucleic Acid Drugs Market Share by Region (2021–2032)

Figure 44. China Nucleic Acid Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 45. Japan Nucleic Acid Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 46. South Korea Nucleic Acid Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 47. Southeast Asia Nucleic Acid Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 48. India Nucleic Acid Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 49. Australia & New Zealand Nucleic Acid Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 50. Latin America Nucleic Acid Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 51. Latin America Nucleic Acid Drugs Market Share by Country (2021–2032)

Figure 52. Mexico Nucleic Acid Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 53. Brazil Nucleic Acid Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 54. Middle East & Africa Nucleic Acid Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 55. Middle East & Africa Nucleic Acid Drugs Market Share by Country (2021–2032)

Figure 56. Israel Nucleic Acid Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 57. Saudi Arabia Nucleic Acid Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 58. UAE Nucleic Acid Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 59. Sarepta Therapeutics Revenue Growth Rate in Nucleic Acid Drugs Business (2021–2026)

Figure 60. Ionis Pharmaceuticals Revenue Growth Rate in Nucleic Acid Drugs Business (2021–2026)

Figure 61. Alnylam Revenue Growth Rate in Nucleic Acid Drugs Business (2021–2026)

Figure 62. Biogen Revenue Growth Rate in Nucleic Acid Drugs Business (2021–2026)

Figure 63. Nippon Shinyaku Revenue Growth Rate in Nucleic Acid Drugs Business (2021–2026)

Figure 64. Sobi Revenue Growth Rate in Nucleic Acid Drugs Business (2021–2026)

Figure 65. Novartis Revenue Growth Rate in Nucleic Acid Drugs Business (2021–2026)

Figure 66. BioNTech Revenue Growth Rate in Nucleic Acid Drugs Business (2021–2026)

Figure 67. Pfizer Revenue Growth Rate in Nucleic Acid Drugs Business (2021–2026)

Figure 68. Moderna Therapeutics Revenue Growth Rate in Nucleic Acid Drugs Business (2021–2026)

Figure 69. Jazz Pharmaceuticals Revenue Growth Rate in Nucleic Acid Drugs Business (2021–2026)

Figure 70. Novo Nordisk Revenue Growth Rate in Nucleic Acid Drugs Business (2021–2026)

Figure 71. AstraZeneca Revenue Growth Rate in Nucleic Acid Drugs Business (2021–2026)

Figure 72. Astellas Pharma Revenue Growth Rate in Nucleic Acid Drugs Business (2021–2026)

Figure 73. Bottom-up and Top-down Approaches for This Report

Figure 74. Data Triangulation

Figure 75. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic

$2900

Single User License

Multi User

Electronic

$4350

Multi User License

Enterprise License

Electronic

$5800

Enterprise License

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Global RNA based Therapeutics Drug Market Research Report 2024

Global Nucleic acid based Therapeutics Drug Market Research Report 2024

Global Nucleic Acid based Therapy Market Research Report 2024

Global Nucleic Acid Medicine Market Research Report 2025

Global Small Interfering RNA siRNA based Therapeutics Market Research Report 2024

Global Low Molecular Weight Nucleic Acid Drugs Market Research Report 2025

Global ASO based Drug Market Research Report 2024

Global RNA Therapeutics Market Research Report 2024

Global Small Interfering RNA siRNA Drugs Market Research Report 2024

Global Antisense Oligonucleotides ASO Therapy Market Research Report 2024

Global Oligonucleotide Oligo Drugs Market Research Report 2024

Global Oligonucleotide Drugs ONs Market Research Report 2025

Global Antisense Oligonucleotides based Therapeutics Market Research Report 2024

Global Small Nucleic Acid Drug Market Research Report 2025

Global Nucleic Acid Based Gene Therapy Market Research Report 2025

Antisense and RNAi Therapeutics Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global RNA Interference RNAi Based Therapeutics Market Research Report 2024

Global Oligonucleotide Therapeutics Market Research Report 2024

Global Antisense Oligonucleotide Therapy for the Nervous System Market Research Report 2024

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions